CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
CO33: Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
CCTG is pleased to announce that the 2020 CCTG Phase III Team Award for Intergroup-Led trials has been awarded to the Saskatoon Cancer Centre MAC.21 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
The team members include: Nayyer Iqbal, Osama Ahmed, Shahid Ahmed, Tehmina Asif, Kamal Haider, Amer Sami, Mita Manna, Andrea Gallivan, Dominique Wagner, Jolene Hicks.
Two CCTG researchers were recently awarded nearly $2 million from the Canadian Cancer Society and the Conquer Cancer-Breast Cancer Research Foundation to support conduct of CCTG Investigational New Drug trials.
After 22 years in his position as QOL committee co-chair, Dr. Michael Brundage is stepping down, to be succeeded by Dr. Winson Cheung.
CO28: NEOadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer: The NEO Trial has been closed to accrual after successfully reaching the accrual goal.
The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep the rectum.
The CCTG Genitourinary Disease Site Committee is very honoured to welcome the new chair and modality sub-chairs.
Primary publication for IND226 and MA33 QoL journal article
The IND216 trial: Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia, has been permanently closed.
About the trial: Buparlisib has been shown to shrink tumours in animals. It has been studied in some people and seems promising but it is not clear if it can offer better results than standard treatment. The standard or usual treatment for this disease is chemotherapy, targeted therapy or radiation, either alone or in combination.
CCTG has developed guidance documents to facilitate continuing patients on trials or how to modify (and document) protocol requirements for individual patient management as needed.
Please note that an updated Frequently Asked Questions (FAQs) document has been posted to the CCTG COVID-19 members webpage. Also new are posted links to the previously communicated important memos dated 2020MAR17, 2020MAR27 and 2020APR06.
